Search
Mexazolam
go.drugbank.com/drugs/DB15489InvestigationalMexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions.
Anthoxanthum odoratum pollen
go.drugbank.com/drugs/DB10404ApprovedAnthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.
Mixtures: K-O-R-T and Sweet Vernal Standardized Grass Pollen Mix, K-O-R-T and Sweet Vernal Standardized Grass Pollen MixDaglutril
go.drugbank.com/drugs/DB05796InvestigationalDaglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
Chlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Ordopidine
go.drugbank.com/drugs/DB05196InvestigationalACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Lysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalExplanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence.
Categories: Heterocyclic Compounds with 4 or More RingsBiochanin A
go.drugbank.com/drugs/DB15334ExperimentalBiochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).
Categories: Compounds used in a research, industrial, or household settingAAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalIt is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752] … AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
SRP-9005
go.drugbank.com/drugs/DB17958InvestigationalDeveloped by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]